Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Guillain-Barre syndrome

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Progressive bilateral weakness with reduced reflexes, facial or bulbar weakness, declining forced vital capacity, ineffective cough, breathlessness when supine, arrhythmia or labile blood pressure requires immediate hospital and neurology assessment. Normal oxygen saturation does not exclude impending ventilatory failure.

Synopsis

Recognise acute inflammatory polyradiculoneuropathy before respiratory collapse, monitor bulbar and autonomic function, and initiate IV immunoglobulin or plasma exchange without relying on late tests.

  • Guillain–Barré syndrome usually causes rapidly progressive, relatively symmetrical limb weakness and areflexia reaching maximum severity within 4 weeks, often after respiratory or gastrointestinal infection.
  • Paraesthesia and severe back or radicular pain are common, but a clear sensory level, early bladder paralysis or persistent marked asymmetry suggests an alternative diagnosis.
  • Facial diplegia, dysphagia, weak neck flexion and inability to lift the head can precede respiratory failure and require frequent bedside reassessment.
  • Measure serial forced vital capacity and inspiratory strength where available; pulse oximetry and arterial gases may remain normal until respiratory muscle failure is advanced.
  • Autonomic involvement causes tachycardia, bradyarrhythmia, blood-pressure swings, ileus, urinary retention and sweating abnormalities and can be life-threatening.
  • CSF often shows raised protein with few cells after the first week, but can be normal early; substantial pleocytosis should redirect investigation towards infection or inflammation.
  • Nerve-conduction studies may show demyelination, conduction block or an axonal subtype and can also be non-diagnostic early, so repeat testing may be needed.
  • Treat non-ambulant or significantly progressive GBS with IV immunoglobulin or plasma exchange through specialist protocols; routine corticosteroids do not improve outcome.
  • Prevent venous thrombosis, pressure injury, contracture and aspiration, treat pain and provide rehabilitation and psychological support while axonal recovery evolves over months.

Key red flags

Ascending weakness

Progressive bilateral leg then arm or cranial weakness with reduced reflexes over days strongly suggests GBS after cord compression and metabolic mimics are considered.

Bulbar and neck weakness

Dysphagia, nasal speech, pooled secretions, weak cough or loss of head lift predicts aspiration and respiratory risk even before obvious breathlessness.

Autonomic instability

Large blood-pressure swings, resting tachycardia, episodic bradycardia, ileus or retention reflects dysautonomia and justifies monitored high-acuity care.

Miller Fisher syndrome

Ophthalmoplegia, sensory ataxia and areflexia with little limb weakness is a recognised GBS-spectrum variant requiring respiratory and bulbar vigilance.

Axonal variant

Profound motor weakness with low compound muscle action potentials and less slowing can represent acute motor axonal or motor-sensory axonal neuropathy.

Diagnostic mismatch

A sensory level, brisk reflexes, severe persistent asymmetry, early sphincter paralysis, fever or marked CSF pleocytosis should trigger investigation for cord, infection or another neuropathy.

Investigation priorities

01
Serial respiratory mechanicsFirst step

Detect declining inspiratory, expiratory and cough strength before gas exchange fails.

Management branches

AdmissionAnticipate respiratory failure

Progressive bilateral weakness and areflexia raises possible GBS.

  1. Admit urgently, document time course and power, reflexes, cranial nerves, neck flexion, cough, swallowing, autonomic symptoms and an alternative central localisation.
  2. Measure FVC and inspiratory or expiratory strength promptly and serially, monitor ECG and blood pressure and obtain critical-care review for decline or bulbar weakness.
  3. Arrange CSF and neurophysiology without delaying treatment, adding spinal imaging and infection or metabolic tests when atypical features occur.
  4. Protect swallowing, secretions, pressure areas and venous circulation while a senior neurology team confirms the immune-treatment plan.

Key medicines

Intravenous human immunoglobulinA standard specialist course totals 2 g/kg, commonly 0.4 g/kg daily for 5 days, using the NHS commissioned weight and product protocol.Review thrombosis, renal impairment, haemolysis, aseptic meningitis, fluid load, IgA-related reaction and live-vaccine timing; monitor infusion. Current NHS England criteria state that a second GBS course is ineffective and may cause harm.
Low-molecular-weight heparin prophylaxisUse the local immobility prophylaxis dose adjusted for body weight, renal function, bleeding risk and planned lumbar or vascular procedures.Coordinate timing with lumbar puncture and central access, monitor platelets or bleeding when indicated and do not use when haemorrhagic risk outweighs benefit.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG127 rapidly progressive weaknessImmediate recognition and referral of possible neuromuscular respiratory disease.
  • NHS England therapeutic immunoglobulin criteria 2025Current commissioned IVIg indication, five-day course, weight method and warning against a second GBS course.
  • Association of British Neurologists guidelinesUK specialist acute inflammatory neuropathy guidance.
  • NHS Guillain-Barre syndromeUK recognition, treatment and recovery information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom